Skip to main content

Table 1 Demographic data, clinical and laboratorial features, outcomes and treatments in childhood-onset systemic lupus erythematosus (cSLE) patients with autoimmune hepatitis (AIH)

From: Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: a multicentric cohort study

  Cases
1 2 3 4 5 6 7
Demographic data
 Age, years 12.5 12.3 10.3 15 10.3 15.6 11.7
 Female gender + + + + + +
 Time between AIH and cSLE, years −1.5 0 −4.75 0 2.3 8.5 0
 cSLE duration, years 0 0 0 0 2.3 8.5 0
Clinical/laboratorial features
 Constitutional symptoms + + + + + +
 Jaundice/ascites +/− −/− +/− +/− −/− +/− +/−
 Hepatomegaly/Splenomegaly −/− +/+ −/− +/+ +/− +/− +/+
 AST, IU/L 93 652 35 345.7 245 4466 1260
 ALT, IU/L 113 268 122 244.6 552 1411 949
 GGT, IU/L 258 604 91 51.2 613 69 606
 Hypergammaglobulinemia + + + + + + +
 ANA > 1:80 + + + + + + +
 Anti-SMA > 1:80 + + +
 Anti-LKM1 > 1:80
 Viral hepatitis markers
 Alcohol intake
 Liver histology with interface hepatitis and lymphocytic infiltrates + + + + + + +
Outcomes
 Liver failure/portal hypertension/cirrhosis - /−/− - /−/− - /−/− - /−/− - /−/− - /−/− - /−/−
 Death
Therapy
 AIH complete response therapy (>  18 months) + NP + NP + + NP
 cSLE treatments PD, AZA PD, AZA, AM PD, AZA, AM PD, AZA PD, AZA, AM PD, AZA PD
  1. AST aspartate aminotransferase (normal value 15–40 IU/L), ALT alanine aminotransferase (normal value 10–40 IU/L), GGT gamma glutamyl transferase (normal value 3–25 IU/L), ANA antinuclear antibodies, anti-SMA - anti-smooth muscle antibody, anti-LKM1 - anti-liver kidney microsomal antibody type1, NP not possible, PD prednisone, AZA azathioprine, AM antimalarial